NL193694C - 5 Gesubstitueerde 3-(aminoalkyl)-1H-indoolderivaten met werking tegen migraine en farmaceutisch preparaat daarvan. - Google Patents
5 Gesubstitueerde 3-(aminoalkyl)-1H-indoolderivaten met werking tegen migraine en farmaceutisch preparaat daarvan. Download PDFInfo
- Publication number
- NL193694C NL193694C NL8302031A NL8302031A NL193694C NL 193694 C NL193694 C NL 193694C NL 8302031 A NL8302031 A NL 8302031A NL 8302031 A NL8302031 A NL 8302031A NL 193694 C NL193694 C NL 193694C
- Authority
- NL
- Netherlands
- Prior art keywords
- hydrogen atom
- solution
- group
- ethanol
- methanesulfonamide
- Prior art date
Links
- 125000004103 aminoalkyl group Chemical group 0.000 title claims description 7
- 230000002460 anti-migrenic effect Effects 0.000 title claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 title description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 238
- 150000001875 compounds Chemical class 0.000 claims description 144
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 84
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 79
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 70
- 239000000047 product Substances 0.000 claims description 69
- 239000000203 mixture Substances 0.000 claims description 41
- -1 N-methyl-3- [2- (phenylmethylideneamino) ethyl] -1 H -indole-5-methanesulfonamide compound Chemical class 0.000 claims description 33
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 32
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 27
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 24
- 238000004458 analytical method Methods 0.000 claims description 23
- 239000000706 filtrate Substances 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 13
- 239000012453 solvate Substances 0.000 claims description 10
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 8
- 239000012458 free base Substances 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 229940054051 antipsychotic indole derivative Drugs 0.000 claims description 5
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 239000002808 molecular sieve Substances 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 239000000243 solution Substances 0.000 description 104
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 96
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 93
- 239000007787 solid Substances 0.000 description 55
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 36
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 34
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 32
- 230000002829 reductive effect Effects 0.000 description 31
- 239000000725 suspension Substances 0.000 description 31
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- 238000000034 method Methods 0.000 description 26
- 239000002904 solvent Substances 0.000 description 25
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 24
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 21
- 239000003054 catalyst Substances 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- 239000000284 extract Substances 0.000 description 18
- 229910052739 hydrogen Inorganic materials 0.000 description 16
- 239000001257 hydrogen Substances 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- 238000004587 chromatography analysis Methods 0.000 description 15
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 15
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 15
- MURZXKIEJFJMPP-UHFFFAOYSA-N 1-[3-(2-aminoethyl)-1h-indol-5-yl]-n-methylmethanesulfonamide Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN)C2=C1 MURZXKIEJFJMPP-UHFFFAOYSA-N 0.000 description 14
- 238000001816 cooling Methods 0.000 description 14
- 239000006260 foam Substances 0.000 description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 13
- 229910021529 ammonia Inorganic materials 0.000 description 13
- 238000006722 reduction reaction Methods 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 12
- 229940109239 creatinine Drugs 0.000 description 12
- 239000011976 maleic acid Substances 0.000 description 12
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 12
- LTLKJYMNUSSFAH-UHFFFAOYSA-N 4-chloro-1,1-dimethoxybutane Chemical compound COC(OC)CCCCl LTLKJYMNUSSFAH-UHFFFAOYSA-N 0.000 description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 11
- 229910052799 carbon Inorganic materials 0.000 description 11
- 239000003480 eluent Substances 0.000 description 11
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 11
- 235000019341 magnesium sulphate Nutrition 0.000 description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- 229910003445 palladium oxide Inorganic materials 0.000 description 10
- JQPTYAILLJKUCY-UHFFFAOYSA-N palladium(ii) oxide Chemical compound [O-2].[Pd+2] JQPTYAILLJKUCY-UHFFFAOYSA-N 0.000 description 10
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 229910052938 sodium sulfate Inorganic materials 0.000 description 9
- 235000011152 sodium sulphate Nutrition 0.000 description 9
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 125000003710 aryl alkyl group Chemical group 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 7
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 6
- 229920000388 Polyphosphate Polymers 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 239000012280 lithium aluminium hydride Substances 0.000 description 6
- 239000001205 polyphosphate Substances 0.000 description 6
- 235000011176 polyphosphates Nutrition 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 235000010288 sodium nitrite Nutrition 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- QTEJRFMIQYQJRM-UHFFFAOYSA-N [3-(2-aminoethyl)-1h-indol-5-yl]methanesulfonamide Chemical compound C1=C(CS(N)(=O)=O)C=C2C(CCN)=CNC2=C1 QTEJRFMIQYQJRM-UHFFFAOYSA-N 0.000 description 5
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 238000007429 general method Methods 0.000 description 5
- YDTVAJYBEHCVJY-UHFFFAOYSA-N n-methyl-1-[3-[2-(methylamino)ethyl]-1h-indol-5-yl]methanesulfonamide Chemical compound C1=C(CS(=O)(=O)NC)C=C2C(CCNC)=CNC2=C1 YDTVAJYBEHCVJY-UHFFFAOYSA-N 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 4
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 4
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 4
- 150000002475 indoles Chemical class 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- 235000011149 sulphuric acid Nutrition 0.000 description 4
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 3
- AMQNZONUQVIKGD-UHFFFAOYSA-N 1-[3-(2-aminoethyl)-1h-indol-5-yl]-n,n-dimethylmethanesulfonamide Chemical compound CN(C)S(=O)(=O)CC1=CC=C2NC=C(CCN)C2=C1 AMQNZONUQVIKGD-UHFFFAOYSA-N 0.000 description 3
- VUYWONZJZHPBIZ-UHFFFAOYSA-N 1-[3-(2-aminoethyl)-1h-indol-5-yl]-n-prop-2-enylmethanesulfonamide Chemical compound C1=C(CS(=O)(=O)NCC=C)C=C2C(CCN)=CNC2=C1 VUYWONZJZHPBIZ-UHFFFAOYSA-N 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 241000400611 Eucalyptus deanei Species 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 3
- 150000001241 acetals Chemical class 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 229960003624 creatine Drugs 0.000 description 3
- 239000006046 creatine Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 150000002431 hydrogen Chemical group 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
- DDJYRBOKFGKZHZ-UHFFFAOYSA-N methanesulfonyl chloride nitrobenzene Chemical compound CS(=O)(=O)Cl.[N+](=O)([O-])C1=CC=CC=C1 DDJYRBOKFGKZHZ-UHFFFAOYSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000010453 quartz Substances 0.000 description 3
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000001119 stannous chloride Substances 0.000 description 3
- 235000011150 stannous chloride Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000001384 succinic acid Substances 0.000 description 3
- 238000001665 trituration Methods 0.000 description 3
- CIWNHTXCBHTWRV-UHFFFAOYSA-N 1-(4-aminophenyl)-n-methylmethanesulfonamide Chemical compound CNS(=O)(=O)CC1=CC=C(N)C=C1 CIWNHTXCBHTWRV-UHFFFAOYSA-N 0.000 description 2
- XDHAKNGXIPRSSX-UHFFFAOYSA-N 1-[3-(2-aminoethyl)-1h-indol-5-yl]-n-(2-phenylethyl)methanesulfonamide Chemical compound C1=C2C(CCN)=CNC2=CC=C1CS(=O)(=O)NCCC1=CC=CC=C1 XDHAKNGXIPRSSX-UHFFFAOYSA-N 0.000 description 2
- KRARMSKMLWBOMY-UHFFFAOYSA-N 1-[3-(2-aminoethyl)-1h-indol-5-yl]-n-cyclohexylmethanesulfonamide Chemical compound C1=C2C(CCN)=CNC2=CC=C1CS(=O)(=O)NC1CCCCC1 KRARMSKMLWBOMY-UHFFFAOYSA-N 0.000 description 2
- PFHJCUVTWFXKEH-UHFFFAOYSA-N 1-[3-(2-aminoethyl)-1h-indol-5-yl]-n-phenylmethanesulfonamide Chemical compound C1=C2C(CCN)=CNC2=CC=C1CS(=O)(=O)NC1=CC=CC=C1 PFHJCUVTWFXKEH-UHFFFAOYSA-N 0.000 description 2
- JKDQZXJVYVRMEZ-UHFFFAOYSA-N 1-[3-(2-chloroethyl)-1h-indol-5-yl]-n-methylmethanesulfonamide Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCCl)C2=C1 JKDQZXJVYVRMEZ-UHFFFAOYSA-N 0.000 description 2
- SEOYZWFXZMRJHB-UHFFFAOYSA-N 1-[3-(3-aminopropyl)-1h-indol-5-yl]-n-methylmethanesulfonamide Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCCN)C2=C1 SEOYZWFXZMRJHB-UHFFFAOYSA-N 0.000 description 2
- NMOCOWABJRWQGY-UHFFFAOYSA-N 2-(4,4-diethoxybutyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCC(OCC)OCC)C(=O)C2=C1 NMOCOWABJRWQGY-UHFFFAOYSA-N 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 2
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- OAMZXMDZZWGPMH-UHFFFAOYSA-N ethyl acetate;toluene Chemical compound CCOC(C)=O.CC1=CC=CC=C1 OAMZXMDZZWGPMH-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- GSYSFVSGPABNNL-UHFFFAOYSA-N methyl 2-dimethoxyphosphoryl-2-(phenylmethoxycarbonylamino)acetate Chemical group COC(=O)C(P(=O)(OC)OC)NC(=O)OCC1=CC=CC=C1 GSYSFVSGPABNNL-UHFFFAOYSA-N 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 125000002560 nitrile group Chemical group 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 229910052703 rhodium Inorganic materials 0.000 description 2
- 239000010948 rhodium Substances 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical group CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- VYLIVAAMSLPRIS-UHFFFAOYSA-N (4-nitrophenyl)methanesulfonamide Chemical compound NS(=O)(=O)CC1=CC=C([N+]([O-])=O)C=C1 VYLIVAAMSLPRIS-UHFFFAOYSA-N 0.000 description 1
- CAXRPEAFHWDFTD-UHFFFAOYSA-N (4-nitrophenyl)methanesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(CS(Cl)(=O)=O)C=C1 CAXRPEAFHWDFTD-UHFFFAOYSA-N 0.000 description 1
- KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 1
- DRKYSGDBANPLKH-UHFFFAOYSA-N 1-(4-aminophenyl)-n,n-dimethylmethanesulfonamide Chemical compound CN(C)S(=O)(=O)CC1=CC=C(N)C=C1 DRKYSGDBANPLKH-UHFFFAOYSA-N 0.000 description 1
- TVKBEJKYEHKAEV-UHFFFAOYSA-N 1-(4-hydrazinylphenyl)-n-(2-phenylethyl)methanesulfonamide Chemical compound C1=CC(NN)=CC=C1CS(=O)(=O)NCCC1=CC=CC=C1 TVKBEJKYEHKAEV-UHFFFAOYSA-N 0.000 description 1
- DZODFXKLAFRYEC-UHFFFAOYSA-N 1-(4-hydrazinylphenyl)-n-methylmethanesulfonamide Chemical compound CNS(=O)(=O)CC1=CC=C(NN)C=C1 DZODFXKLAFRYEC-UHFFFAOYSA-N 0.000 description 1
- WZZPGBAXFSIKJJ-UHFFFAOYSA-N 1-(4-hydrazinylphenyl)-n-methylmethanesulfonamide;hydrochloride Chemical compound Cl.CNS(=O)(=O)CC1=CC=C(NN)C=C1 WZZPGBAXFSIKJJ-UHFFFAOYSA-N 0.000 description 1
- POHPAZAAIWIYOS-UHFFFAOYSA-N 1-(4-nitrophenyl)-n-(2-phenylethyl)methanesulfonamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1CS(=O)(=O)NCCC1=CC=CC=C1 POHPAZAAIWIYOS-UHFFFAOYSA-N 0.000 description 1
- DEBUYIPOYKBSHR-UHFFFAOYSA-N 1-(4-nitrophenyl)-n-propan-2-ylmethanesulfonamide Chemical compound CC(C)NS(=O)(=O)CC1=CC=C([N+]([O-])=O)C=C1 DEBUYIPOYKBSHR-UHFFFAOYSA-N 0.000 description 1
- DTWQYCXSPPQEEP-BTJKTKAUSA-N 1-[3-(2-aminoethyl)-1H-indol-5-yl]-N-ethylmethanesulfonamide (Z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.CCNS(=O)(=O)CC1=CC=C2NC=C(CCN)C2=C1 DTWQYCXSPPQEEP-BTJKTKAUSA-N 0.000 description 1
- YSVQPMMNVLTTDF-UHFFFAOYSA-N 1-[3-(2-aminoethyl)-1h-indol-5-yl]-n-benzylmethanesulfonamide Chemical compound C1=C2C(CCN)=CNC2=CC=C1CS(=O)(=O)NCC1=CC=CC=C1 YSVQPMMNVLTTDF-UHFFFAOYSA-N 0.000 description 1
- QDSHOIPJHLYFPZ-UHFFFAOYSA-N 1-[3-(2-aminoethyl)-1h-indol-5-yl]-n-ethylmethanesulfonamide Chemical compound CCNS(=O)(=O)CC1=CC=C2NC=C(CCN)C2=C1 QDSHOIPJHLYFPZ-UHFFFAOYSA-N 0.000 description 1
- AFBYMGMXBHJYHZ-UHFFFAOYSA-N 1-[3-(2-aminoethyl)-1h-indol-5-yl]-n-propan-2-ylmethanesulfonamide Chemical compound CC(C)NS(=O)(=O)CC1=CC=C2NC=C(CCN)C2=C1 AFBYMGMXBHJYHZ-UHFFFAOYSA-N 0.000 description 1
- HYBOCMIZDNGJEY-UHFFFAOYSA-N 1-[3-(cyanomethyl)-1h-indol-5-yl]-n-methylmethanesulfonamide Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CC#N)C2=C1 HYBOCMIZDNGJEY-UHFFFAOYSA-N 0.000 description 1
- HTPOOUOLROIBLP-UHFFFAOYSA-N 1-[3-[3-(1,3-dioxoisoindol-2-yl)propyl]-1h-indol-5-yl]-n-methylmethanesulfonamide Chemical compound O=C1C2=CC=CC=C2C(=O)N1CCCC1=CNC2=CC=C(CS(=O)(=O)NC)C=C21 HTPOOUOLROIBLP-UHFFFAOYSA-N 0.000 description 1
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 description 1
- XMBRLURMRGTDJK-UHFFFAOYSA-N 1h-indol-5-ylmethanesulfonamide Chemical compound NS(=O)(=O)CC1=CC=C2NC=CC2=C1 XMBRLURMRGTDJK-UHFFFAOYSA-N 0.000 description 1
- HORQAOAYAYGIBM-UHFFFAOYSA-N 2,4-dinitrophenylhydrazine Chemical compound NNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O HORQAOAYAYGIBM-UHFFFAOYSA-N 0.000 description 1
- BOURNSWDLZGGGR-UHFFFAOYSA-N 2-(5,5-dimethoxypentyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCCC(OC)OC)C(=O)C2=C1 BOURNSWDLZGGGR-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- PEXCMMDHBIFUIJ-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;sulfuric acid Chemical class OS(O)(=O)=O.NC(=N)N(C)CC(O)=O PEXCMMDHBIFUIJ-UHFFFAOYSA-N 0.000 description 1
- MEVXSUZBFYZPHZ-UHFFFAOYSA-N 2-amino-3-methyl-4h-imidazol-5-one;sulfuric acid Chemical compound OS(O)(=O)=O.CN1CC(=O)N=C1N MEVXSUZBFYZPHZ-UHFFFAOYSA-N 0.000 description 1
- SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 1
- JRASUUTVFCLPPO-UHFFFAOYSA-N 3-(2-chloroethyl)-1h-indole Chemical compound C1=CC=C2C(CCCl)=CNC2=C1 JRASUUTVFCLPPO-UHFFFAOYSA-N 0.000 description 1
- MPFLMSMVNIRCJA-UHFFFAOYSA-N 4-nitrobutanal Chemical compound [O-][N+](=O)CCCC=O MPFLMSMVNIRCJA-UHFFFAOYSA-N 0.000 description 1
- GDVDQWWINLDHSX-UHFFFAOYSA-N 5-bromo-1,1-dimethoxypentane Chemical compound COC(OC)CCCCBr GDVDQWWINLDHSX-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- NOTFZGFABLVTIG-UHFFFAOYSA-N Cyclohexylethyl acetate Chemical compound CC(=O)OCCC1CCCCC1 NOTFZGFABLVTIG-UHFFFAOYSA-N 0.000 description 1
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 1
- 238000006783 Fischer indole synthesis reaction Methods 0.000 description 1
- 229930195212 Fischerindole Natural products 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GWESVXSMPKAFAS-UHFFFAOYSA-N Isopropylcyclohexane Natural products CC(C)C1CCCCC1 GWESVXSMPKAFAS-UHFFFAOYSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000000944 Soxhlet extraction Methods 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- BMARSMWEKUKVPR-UHFFFAOYSA-N [3-(cyanomethyl)-1h-indol-5-yl]methanesulfonamide Chemical compound NS(=O)(=O)CC1=CC=C2NC=C(CC#N)C2=C1 BMARSMWEKUKVPR-UHFFFAOYSA-N 0.000 description 1
- LDJFJYQBRGUAHN-UHFFFAOYSA-N [3-[2-(1,3-dioxoisoindol-2-yl)ethyl]-1h-indol-5-yl]methanesulfonamide Chemical compound O=C1C2=CC=CC=C2C(=O)N1CCC1=CNC2=CC=C(CS(=O)(=O)N)C=C21 LDJFJYQBRGUAHN-UHFFFAOYSA-N 0.000 description 1
- IZEQRYXPOFFPCG-UHFFFAOYSA-N [3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]methanesulfonamide Chemical compound C1=C(CS(N)(=O)=O)C=C2C(CCN(C)C)=CNC2=C1 IZEQRYXPOFFPCG-UHFFFAOYSA-N 0.000 description 1
- XSAQRHXZEWBHSJ-UHFFFAOYSA-N [3-[2-(ethylamino)ethyl]-1h-indol-5-yl]methanesulfonamide Chemical compound C1=C(CS(N)(=O)=O)C=C2C(CCNCC)=CNC2=C1 XSAQRHXZEWBHSJ-UHFFFAOYSA-N 0.000 description 1
- LJBOWIAGZOMTMF-UHFFFAOYSA-N [3-[2-(methylamino)ethyl]-1h-indol-5-yl]methanesulfonamide Chemical compound C1=C(CS(N)(=O)=O)C=C2C(CCNC)=CNC2=C1 LJBOWIAGZOMTMF-UHFFFAOYSA-N 0.000 description 1
- DXGTUUQHTDOFFQ-UHFFFAOYSA-N [N].C1=CC=C2NC=CC2=C1 Chemical group [N].C1=CC=C2NC=CC2=C1 DXGTUUQHTDOFFQ-UHFFFAOYSA-N 0.000 description 1
- NPHRGEZGUMJYJH-UHFFFAOYSA-N [Pt].[I] Chemical compound [Pt].[I] NPHRGEZGUMJYJH-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 125000004682 aminothiocarbonyl group Chemical group NC(=S)* 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- MFGFQKUBQDUFEW-UHFFFAOYSA-N aniline methanesulfonamide Chemical compound NC1=CC=CC=C1.CS(=O)(=O)N MFGFQKUBQDUFEW-UHFFFAOYSA-N 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- 229940045348 brown mixture Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- WACQKHWOTAEEFS-UHFFFAOYSA-N cyclohexane;ethyl acetate Chemical compound CCOC(C)=O.C1CCCCC1 WACQKHWOTAEEFS-UHFFFAOYSA-N 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- XBECWGJPSXHFCS-UHFFFAOYSA-N imidazole-1-carbaldehyde Chemical compound O=CN1C=CN=C1 XBECWGJPSXHFCS-UHFFFAOYSA-N 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- AONCEJAWTUBEEK-UHFFFAOYSA-N methanesulfonamide phenylhydrazine hydrochloride Chemical compound Cl.C1(=CC=CC=C1)NN.CS(=O)(=O)N AONCEJAWTUBEEK-UHFFFAOYSA-N 0.000 description 1
- VUQUOGPMUUJORT-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1 VUQUOGPMUUJORT-UHFFFAOYSA-N 0.000 description 1
- 229960001186 methysergide Drugs 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- XCHBZJJWNKOQMT-UHFFFAOYSA-N n-[2-[5-(methylsulfamoylmethyl)-1h-indol-3-yl]ethyl]formamide Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCNC=O)C2=C1 XCHBZJJWNKOQMT-UHFFFAOYSA-N 0.000 description 1
- KZWPBAASZYQWIV-UHFFFAOYSA-N n-methyl-1-(4-nitrophenyl)methanesulfonamide Chemical compound CNS(=O)(=O)CC1=CC=C([N+]([O-])=O)C=C1 KZWPBAASZYQWIV-UHFFFAOYSA-N 0.000 description 1
- WVJHETOWFTYSIE-UHFFFAOYSA-N n-methyl-1-[3-(2-nitroethyl)-1h-indol-5-yl]methanesulfonamide Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CC[N+]([O-])=O)C2=C1 WVJHETOWFTYSIE-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 230000006103 sulfonylation Effects 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8216526 | 1982-06-07 | ||
| GB8216526 | 1982-06-07 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NL8302031A NL8302031A (nl) | 1984-01-02 |
| NL193694B NL193694B (nl) | 2000-03-01 |
| NL193694C true NL193694C (nl) | 2000-07-04 |
Family
ID=10530876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8302031A NL193694C (nl) | 1982-06-07 | 1983-06-07 | 5 Gesubstitueerde 3-(aminoalkyl)-1H-indoolderivaten met werking tegen migraine en farmaceutisch preparaat daarvan. |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US4816470A (fr) |
| JP (1) | JPS5942366A (fr) |
| KR (1) | KR900006681B1 (fr) |
| AT (1) | AT381933B (fr) |
| AU (1) | AU566149B2 (fr) |
| BE (1) | BE896986A (fr) |
| CA (1) | CA1199643A (fr) |
| CH (1) | CH657359A5 (fr) |
| CY (1) | CY1458A (fr) |
| CZ (1) | CZ280529B6 (fr) |
| DE (2) | DE19375045I2 (fr) |
| DK (1) | DK260183D0 (fr) |
| DO (1) | DOP1989476000A (fr) |
| ES (3) | ES523039A0 (fr) |
| FI (1) | FI79530C (fr) |
| FR (1) | FR2530625B1 (fr) |
| GB (1) | GB2124210B (fr) |
| GR (1) | GR79215B (fr) |
| HK (1) | HK14789A (fr) |
| IE (1) | IE55358B1 (fr) |
| IL (1) | IL68913A (fr) |
| IT (1) | IT1170387B (fr) |
| KE (1) | KE3833A (fr) |
| LU (1) | LU84852A1 (fr) |
| MX (1) | MX9202623A (fr) |
| MY (1) | MY8700179A (fr) |
| NL (1) | NL193694C (fr) |
| NZ (1) | NZ204482A (fr) |
| PH (1) | PH19908A (fr) |
| PT (1) | PT76830B (fr) |
| SE (1) | SE452459B (fr) |
| SK (1) | SK277877B6 (fr) |
| ZA (1) | ZA834110B (fr) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8332434D0 (en) * | 1983-12-06 | 1984-01-11 | Glaxo Group Ltd | Production of chemical compounds |
| GB8332437D0 (en) * | 1983-12-06 | 1984-01-11 | Glaxo Group Ltd | Chemical compounds |
| HU196752B (en) * | 1983-12-06 | 1989-01-30 | Glaxo Group Ltd | Process for production of medical compositions containing indole-derivatives and these compounds |
| GB8419575D0 (en) * | 1984-08-01 | 1984-09-05 | Glaxo Group Ltd | Chemical compounds |
| GB8601959D0 (en) * | 1986-01-28 | 1986-03-05 | Glaxo Group Ltd | Indole derivatives |
| US5270333A (en) * | 1986-01-28 | 1993-12-14 | Glaxo Group Limited | Indole derivatives |
| GB8615599D0 (en) * | 1986-06-26 | 1986-07-30 | Glaxo Group Ltd | Chemical compounds |
| ES2058292T3 (es) * | 1987-08-13 | 1994-11-01 | Glaxo Group Ltd | Derivados de indol. |
| GB8719167D0 (en) * | 1987-08-13 | 1987-09-23 | Glaxo Group Ltd | Chemical compounds |
| US5225431A (en) * | 1987-10-23 | 1993-07-06 | Burroughs Wellcome Co. | Therapeutic substituted indole compounds and compositions thereof |
| GB8903036D0 (en) * | 1989-02-10 | 1989-03-30 | Glaxo Group Ltd | Chemical compounds |
| HUT57185A (en) * | 1990-03-21 | 1991-11-28 | Merrell Dow Pharma | Process for producing 8-sulfamil-methylen-2-amino-tetraline derivatives and pharmaceutical compositions containing them |
| US5155218A (en) * | 1990-05-08 | 1992-10-13 | Neurogenetic Corporation | Dna encoding human 5-ht1d receptors |
| US5935925A (en) * | 1990-05-08 | 1999-08-10 | Synaptic Pharmaceutical Corporation | Methods of treating migraine and compounds useful for such methods |
| ATE156823T1 (de) * | 1990-06-07 | 1997-08-15 | Zeneca Ltd | Therapeutische heterocyclische verbindungen |
| GB9013845D0 (en) * | 1990-06-21 | 1990-08-15 | Glaxo Group Ltd | Process |
| CA2043709C (fr) * | 1990-06-29 | 2002-01-22 | David W. Smith | Derives pour combattre la migraine d'alcoxypirimidine |
| US5077293A (en) * | 1990-06-29 | 1991-12-31 | Bristol-Myers Squibb Co. | 1-indolyalkyl-4-(alkoxypyrimidinyl)piperazines |
| GB9022250D0 (en) * | 1990-10-12 | 1990-11-28 | Glaxo Group Ltd | Medicaments |
| GB9103770D0 (en) * | 1991-02-22 | 1991-04-10 | Glaxo Group Ltd | Chemical compounds |
| GB9104890D0 (en) * | 1991-03-08 | 1991-04-24 | Glaxo Group Ltd | Compositions |
| CA2084531A1 (fr) * | 1991-12-19 | 1993-06-20 | David W. Smith | Derives antimigraines 4-pyrimidinyle et pyridinyle d'indol-3yl-alkylpiperazines |
| GB9209882D0 (en) * | 1992-05-07 | 1992-06-24 | Glaxo Lab Sa | Compositions |
| GB9211276D0 (en) * | 1992-05-28 | 1992-07-15 | Glaxo Lab Sa | Pharmaceutical compositions |
| GB9211277D0 (en) | 1992-05-28 | 1992-07-15 | Glaxo Group Inc | Pharmaceutical compositions |
| ES2055651B1 (es) * | 1992-07-20 | 1995-03-01 | Vita Invest Sa | Procedimiento para la obtencion de nuevas amidinas derivadas de 3-aminoetilindoles. |
| GB9216009D0 (en) * | 1992-07-28 | 1992-09-09 | Almirall Lab | New indol derivatives |
| ES2056025B1 (es) * | 1992-10-08 | 1995-05-01 | Almirall Lab | Nuevos derivados de indol. |
| US5382592A (en) * | 1993-09-16 | 1995-01-17 | Bristol-Myers Squibb Company | Antimigraine cyclobutenedione derivatives of tryptamines |
| US5468768A (en) * | 1994-01-06 | 1995-11-21 | Bristol-Myers Squibb Company | Antimigraine derivatives of indolylcycloalkanylamines |
| ES2079323B1 (es) * | 1994-06-21 | 1996-10-16 | Vita Invest Sa | Derivados de indol utiles para el tratamiento de la migraña, composicion y uso correspondientes. |
| FR2731224B1 (fr) * | 1995-03-02 | 1997-05-30 | Pf Medicament | Nouveaux derives bi-tryptaminiques sulfonamides, leur procede de preparation et leur utilisation a titre de medicaments |
| US5618816A (en) * | 1995-03-02 | 1997-04-08 | Bristol-Myers Squibb Company | Antimigraine 1,2,5-thiadiazole derivatives of indolylalkyl-pyridnyl and pyrimidinylpiperazines |
| US6586458B1 (en) | 1996-08-16 | 2003-07-01 | Pozen Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
| US5872145A (en) * | 1996-08-16 | 1999-02-16 | Pozen, Inc. | Formulation of 5-HT agonist and NSAID for treatment of migraine |
| US8022095B2 (en) | 1996-08-16 | 2011-09-20 | Pozen, Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
| US6416472B1 (en) | 1997-11-06 | 2002-07-09 | Edus Inc. | Method and device for measuring cognitive efficiency |
| US7189753B1 (en) | 1997-11-06 | 2007-03-13 | Cady Roger K | Preemptive prophylaxis of migraine |
| US6066092A (en) * | 1997-11-06 | 2000-05-23 | Cady; Roger K. | Preemptive prophylaxis of migraine device and method |
| GB9926250D0 (en) * | 1999-11-06 | 2000-01-12 | Knoll Ag | Chemical process |
| US20020099059A1 (en) * | 2000-08-23 | 2002-07-25 | Joel Saper | Combination therapy for the treatment of migraine |
| CN1536986B (zh) * | 2001-03-27 | 2012-07-04 | 沃纳奇尔科特(爱尔兰)有限公司 | 用于抗微生物剂给药的阴道内药物递送装置 |
| US8329734B2 (en) * | 2009-07-27 | 2012-12-11 | Afgin Pharma Llc | Topical therapy for migraine |
| US20030013753A1 (en) * | 2001-06-05 | 2003-01-16 | Ronald Aung-Din | Transdermal migraine therapy |
| EP2316468A1 (fr) | 2002-02-22 | 2011-05-04 | Shire LLC | Système de distribution et méthodes de protection et d'administration de dextroamphetamine |
| WO2003105836A1 (fr) * | 2002-06-13 | 2003-12-24 | Dr. Reddy's Laboratories Limited | 3-'2-(dimethylamino)ethyl-n-methyl-1h-indole-5-methanesulfonamide et succinate correspondant |
| US20040068000A1 (en) * | 2002-10-02 | 2004-04-08 | Mintong Guo | Compression coated tablets |
| US7645886B2 (en) | 2002-12-20 | 2010-01-12 | Ciba Specialty Corporation | Synthesis of amines and intermediates for the synthesis thereof |
| ES2380827T3 (es) | 2002-12-26 | 2012-05-18 | Pozen, Inc. | Formas de dosificación con múltiples capas que contienen naproxeno y triptanes |
| US20080213363A1 (en) * | 2003-01-23 | 2008-09-04 | Singh Nikhilesh N | Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa |
| WO2004076403A1 (fr) * | 2003-02-24 | 2004-09-10 | Transform Pharmaceuticals, Inc. | Formes cristallines du sumatriptan, compositions pharmaceutiques et procedes |
| BRPI0410807A (pt) * | 2003-06-06 | 2006-06-27 | Glaxo Group Ltd | composição farmacêutica, e, método pata tratar um mamìfero sofrendo de ou susceptìvel a condições associadas com dor cefálica |
| WO2004112723A2 (fr) * | 2003-06-20 | 2004-12-29 | Ronald Aung-Din | Therapie locale pour le traitement des migraines, des claquages musculaires, des spasmes musculaires, de la spasticite et d'etats apparentes |
| NZ546182A (en) * | 2003-09-26 | 2009-08-28 | Alza Corp | Controlled release formulations of opioid and nonopioid analgesics such as hydrocodone and acetaminophen |
| WO2005030182A1 (fr) * | 2003-09-26 | 2005-04-07 | Alza Corporation | Formulations a liberation commandee presentant un taux croisssant de liberation |
| EP1708684A2 (fr) | 2003-09-26 | 2006-10-11 | Alza Corporation | Enrobage de medicaments a charge medicamenteuse elevee et procedes de fabrication |
| JP5670609B2 (ja) * | 2003-09-26 | 2015-02-18 | アルザ・コーポレーシヨン | 有効成分の制御送達のためのｏｒｏｓプッシュ−スティック |
| US20060002989A1 (en) * | 2004-06-10 | 2006-01-05 | Ahmed Salah U | Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same |
| US8541026B2 (en) * | 2004-09-24 | 2013-09-24 | Abbvie Inc. | Sustained release formulations of opioid and nonopioid analgesics |
| ATE489138T1 (de) * | 2005-04-13 | 2010-12-15 | Neuraxon Inc | Substituierte indolverbindungen mit nos-hemmender aktivität |
| US20070166336A1 (en) * | 2005-12-13 | 2007-07-19 | David Delmarre | Stable and palatable oral liquid sumatriptan compositions |
| JP5350219B2 (ja) * | 2006-04-13 | 2013-11-27 | ニューラクソン，インコーポレーテッド | Ｎｏｓ阻害活性を有する１，５および３，６−置換インドール化合物 |
| CN101687788A (zh) * | 2006-10-19 | 2010-03-31 | 奥斯拜客斯制药有限公司 | 取代的吲哚 |
| US20090131503A1 (en) * | 2007-11-16 | 2009-05-21 | Annedi Subhash C | 3,5 - substituted indole compounds having nos and norepinephrine reuptake inhibitory activity |
| US20090163451A1 (en) * | 2007-11-16 | 2009-06-25 | Frank Porreca | Methods for treating visceral pain |
| WO2009062319A1 (fr) * | 2007-11-16 | 2009-05-22 | Neuraxon, Inc. | Composés d'indole et procédés de traitement de la douleur viscérale |
| US20090252791A1 (en) * | 2008-04-02 | 2009-10-08 | Venkata Nookaraju Sreedharala | Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug |
| BRPI0912038A2 (pt) | 2008-05-27 | 2017-06-20 | Biota Scient Management Pty Ltd | composto, mistura, composição farmacêutica, uso do composto, e, métodos para tratar e evitar uma infecção por picornavírus, e para formar o composto |
| EP2306998A4 (fr) * | 2008-06-20 | 2011-06-15 | Alphapharm Pty Ltd | Formulation pharmaceutique |
| AU2009269129B2 (en) * | 2008-06-30 | 2015-08-20 | Afgin Pharma, Llc | Topical regional neuro-affective therapy |
| US9211282B2 (en) | 2009-09-25 | 2015-12-15 | Dr. Reddy's Laboratories Ltd. | Formulations comprising triptan compounds |
| US11337962B2 (en) | 2009-09-25 | 2022-05-24 | Upsher-Smith Laboratories, Llc | Formulations comprising triptan compounds |
| US10383816B2 (en) | 2015-03-02 | 2019-08-20 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with cannabinoid combination products |
| US20160256410A1 (en) | 2015-03-02 | 2016-09-08 | Afgin Pharma, Llc | Topical regional neuro-affective therapy in mammals with cannabinoids |
| US10537554B2 (en) * | 2015-08-05 | 2020-01-21 | Upsher-Smith Laboratories, Llc | Pharmaceutical composition for treating migraine |
| WO2017130141A1 (fr) | 2016-01-27 | 2017-08-03 | Instar Technologies A.S. | Supports nanofibreux oromumuqueux pour traitement thérapeutique |
| US20180049994A1 (en) | 2016-08-16 | 2018-02-22 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with caryophyllene |
| EP3766483A1 (fr) | 2019-07-19 | 2021-01-20 | BioPharma Synergies, S. L. | Composition de poudre orodispersible comprenant un triptane |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA795239B (en) * | 1978-10-12 | 1980-11-26 | Glaxo Group Ltd | Heterocyclic compounds |
| NL8103769A (nl) * | 1980-08-12 | 1982-03-01 | Glaxo Group Ltd | Heterocyclische verbindingen, werkwijze ter bereiding daarvan alsmede farmaceutische preparaten die deze verbindingen als actieve component bevatten. |
| ZW19381A1 (en) * | 1980-08-12 | 1983-03-09 | Glaxo Group Ltd | Heterocyclic compounds |
| GB2082175B (en) * | 1980-08-12 | 1984-05-02 | Glaxo Group Ltd | Heterocyclic compounds |
| IT1171450B (it) * | 1980-08-12 | 1987-06-10 | Glaxo Group Ltd | Composti eterociclici indolici, procedimento per produrli e composizioni farmaceutiche che li contengono |
-
1983
- 1983-06-03 IT IT48422/83A patent/IT1170387B/it active Protection Beyond IP Right Term
- 1983-06-03 GR GR71558A patent/GR79215B/el unknown
- 1983-06-06 DK DK2601/83A patent/DK260183D0/da not_active Application Discontinuation
- 1983-06-07 PH PH29020A patent/PH19908A/en unknown
- 1983-06-07 DE DE1993175045 patent/DE19375045I2/de active Active
- 1983-06-07 BE BE0/210953A patent/BE896986A/fr not_active IP Right Cessation
- 1983-06-07 JP JP58101587A patent/JPS5942366A/ja active Granted
- 1983-06-07 NL NL8302031A patent/NL193694C/nl not_active IP Right Cessation
- 1983-06-07 PT PT76830A patent/PT76830B/pt unknown
- 1983-06-07 GB GB08315564A patent/GB2124210B/en not_active Expired
- 1983-06-07 FI FI832035A patent/FI79530C/fi not_active IP Right Cessation
- 1983-06-07 DE DE19833320521 patent/DE3320521A1/de active Granted
- 1983-06-07 LU LU84852A patent/LU84852A1/fr unknown
- 1983-06-07 CA CA000429902A patent/CA1199643A/fr not_active Expired
- 1983-06-07 IE IE1335/83A patent/IE55358B1/en not_active IP Right Cessation
- 1983-06-07 KR KR1019830002526A patent/KR900006681B1/ko not_active IP Right Cessation
- 1983-06-07 IL IL68913A patent/IL68913A/xx not_active IP Right Cessation
- 1983-06-07 SE SE8303208A patent/SE452459B/sv not_active IP Right Cessation
- 1983-06-07 FR FR8309429A patent/FR2530625B1/fr not_active Expired
- 1983-06-07 ES ES523039A patent/ES523039A0/es active Granted
- 1983-06-07 NZ NZ204482A patent/NZ204482A/en unknown
- 1983-06-07 CH CH3117/83A patent/CH657359A5/fr not_active IP Right Cessation
- 1983-06-07 AU AU15441/83A patent/AU566149B2/en not_active Expired
- 1983-06-07 AT AT0208483A patent/AT381933B/de not_active IP Right Cessation
- 1983-06-07 ZA ZA834110A patent/ZA834110B/xx unknown
-
1984
- 1984-02-16 ES ES529802A patent/ES8601880A1/es not_active Expired
-
1985
- 1985-06-17 ES ES544281A patent/ES8609247A1/es not_active Expired
- 1985-11-15 US US06/789,831 patent/US4816470A/en not_active Expired - Lifetime
-
1987
- 1987-12-30 MY MY179/87A patent/MY8700179A/xx unknown
-
1988
- 1988-09-30 KE KE3833A patent/KE3833A/xx unknown
-
1989
- 1989-02-16 HK HK147/89A patent/HK14789A/xx not_active IP Right Cessation
- 1989-07-21 CY CY1458A patent/CY1458A/xx unknown
- 1989-11-20 DO DO4760001989A patent/DOP1989476000A/es unknown
-
1991
- 1991-12-23 SK SK4040-91A patent/SK277877B6/sk unknown
- 1991-12-23 CZ CS914040A patent/CZ280529B6/cs unknown
-
1992
- 1992-06-02 MX MX9202623A patent/MX9202623A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL193694C (nl) | 5 Gesubstitueerde 3-(aminoalkyl)-1H-indoolderivaten met werking tegen migraine en farmaceutisch preparaat daarvan. | |
| US6207836B1 (en) | Indolin-2-one derivatives | |
| EP0950047B1 (fr) | Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| HU196752B (en) | Process for production of medical compositions containing indole-derivatives and these compounds | |
| EP1706113B1 (fr) | Procede servant a preparer 4-(2-dipropylaminoethyl)-1,3-dihydro-2h-indol-2-one chlorhydrate | |
| CA1169428A (fr) | Derives d'indole | |
| GB2081717A (en) | Hereocyclic compounds | |
| NL8700026A (nl) | Indoolderivaten, werkwijze ter bereiding daarvan, alsmede daarop gebaseerde farmaceutische preparaten. | |
| FR2676054A1 (fr) | Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| DK157995B (da) | Analogifremgangsmaade til fremstilling af indolderivater | |
| WO2006075139A2 (fr) | Procede nouveau | |
| US4997845A (en) | β-alkylmelatonins as ovulation inhibitors | |
| NL8700027A (nl) | Chemische verbindingen. | |
| TWI290554B (en) | Process for preparation 5-(1-piperazinyl)-benzofuran-2-carboxamide by transition metal-catalyzed amination | |
| CA1299174C (fr) | Alkylmelatonines | |
| EP1420028A2 (fr) | Procédé de synthèse du perindopril et de ses sels pharmaceutiquement acceptables | |
| NL8701372A (nl) | Indoolderivaten, werkwijze ter bereiding daarvan alsmede farmaceutische preparaten die deze derivaten als actieve component bevatten. | |
| AU735516B2 (en) | Process for preparing 4-substituted-1H-indole-3-glyoxamides | |
| US4876267A (en) | 5-Aminosulphoryl substituted indole derivatives | |
| JP2001270863A (ja) | ６−置換インドール誘導体の製造方法 | |
| HU194164B (en) | Process for production of 1,2-dihydroxi-3-//2-indolil-1,1-dialkyl-ethil/-amin/-prophanes | |
| JP3046463B2 (ja) | ２−アミノ−５，６−ジメトキシ−テトラリンの製造方法 | |
| FI77017C (fi) | Foerfarande foer framstaellning av fenyletanolaminer. | |
| EP0244085A2 (fr) | Dérivés de 3-(2-aminoéthyl)indole | |
| Zvilichovsky | Modified Lossen rearrangement of malonohydroxamic acid. Preparation and properties of 3-(p-tolylsulfonyloxy) hydantoin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A85 | Still pending on 85-01-01 | ||
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| V4 | Discontinued because of reaching the maximum lifetime of a patent |
Effective date: 20030607 |